Gene · 8405
Papers2,215
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
321 to 340 of 2,215
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| HIB/SPOP inhibits Ci/Gli-mediated tumorigenesis by modulating the RNA Polymerase II components stabilities. | iScience | 2023 | 37554435 | PubTator, text mining | PubMed |
| BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype. | EBioMedicine | 2023 | 37549632 | PubTator, text mining | PubMed |
| Single-cell trajectory analysis reveals a CD9 positive state to contribute to exit from stem cell-like and embryonic diapause states and transit to drug-resistant states. | Cell Death Discov | 2023 | 37542044 | PubTator, text mining | PubMed |
| Editorial: Regulation and dysfunction of CSK and CHK. | Front Cell Dev Biol | 2023 | 37538399 | PubTator, text mining | PubMed |
| Cell-free DNA in the management of prostate cancer: Current status and future prospective. | Asian J Urol | 2023 | 37538150 | PubTator, text mining | PubMed |
| Cooperative activation of PDK1 and AKT by MAPK4 enhances cancer growth and resistance to therapy. | PLoS Biol | 2023 | 37531320 | PubTator, text mining | PubMed |
| Inhibition of CDC20 potentiates anti-tumor immunity through facilitating GSDME-mediated pyroptosis in prostate cancer. | Exp Hematol Oncol | 2023 | 37528490 | PubTator, text mining | PubMed |
| Progress of regulatory RNA in small extracellular vesicles in colorectal cancer. | Front Cell Dev Biol | 2023 | 37519298 | PubTator, text mining | PubMed |
| DNA Damage Repair Pathways in Prostate Cancer: A Narrative Review of Molecular Mechanisms, Emerging Biomarkers and Therapeutic Targets in Precision Oncology. | Int J Mol Sci | 2023 | 37511177 | PubTator, text mining | PubMed |
| Unravelling the Role of P300 and TMPRSS2 in Prostate Cancer: A Literature Review. | Int J Mol Sci | 2023 | 37511059 | PubTator, text mining | PubMed |
| Update on Molecular Diagnostics in Thyroid Pathology: A Review. | Genes (Basel) | 2023 | 37510219 | PubTator, text mining | PubMed |
| CDC20 Is Regulated by the Histone Methyltransferase, KMT5A, in Castration-Resistant Prostate Cancer. | Cancers (Basel) | 2023 | 37509260 | PubTator, text mining | PubMed |
| Epigenetic Reader Bromodomain-Containing Protein 4 in Aging-Related Vascular Pathologies and Diseases: Molecular Basis, Functional Relevance, and Clinical Potential. | Biomolecules | 2023 | 37509171 | PubTator, text mining | PubMed |
| Nuclear Phosphoinositides as Key Determinants of Nuclear Functions. | Biomolecules | 2023 | 37509085 | PubTator, text mining | PubMed |
| Integration analysis of senescence-related genes to predict prognosis and immunotherapy response in soft-tissue sarcoma: evidence based on machine learning and experiments. | Front Pharmacol | 2023 | 37497116 | PubTator, text mining | PubMed |
Identification of novel and potent dual-targeting HDAC1/SPOP inhibitors using structure-based virtual screening, molecular dynamics simulation and evaluation of in vitro and in vivo antitumor activity. | Front Pharmacol | 2023 | 37492092 | PubTator, text mining | PubMed |
| Evaluation of somatic mutations in cervicovaginal samples as a non-invasive method for the detection and molecular classification of endometrial cancer. | EBioMedicine | 2023 | 37480623 | PubTator, text mining | PubMed |
| Beyond canonical PROTAC: biological targeted protein degradation (bioTPD). | Biomater Res | 2023 | 37480049 | PubTator, text mining | PubMed |
| Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer. | Cancer Cell | 2023 | 37478850 | PubTator, text mining | PubMed |
| Unique Spectrum of Activating BRAF Alterations in Prostate Cancer. | Clin Cancer Res | 2023 | 37477913 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8405/papers?page=17